Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Long-Term Debt Repayments (2022 - 2025)

Cytokinetics (CYTK) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $4.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $4.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.8 million, a N/A change, with the full-year FY2025 number at $10.8 million, up 24.54% from a year prior.
  • Long-Term Debt Repayments was $4.8 million for Q4 2025 at Cytokinetics, up from $2.7 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $47.7 million in Q1 2022 to a low of $705000.0 in Q1 2024.
  • A 3-year average of $10.2 million and a median of $2.7 million in 2024 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 280.43% in 2025; the steepest drop was 280.43% in 2025.
  • Cytokinetics' Long-Term Debt Repayments stood at $47.7 million in 2022, then plummeted by 94.42% to $2.7 million in 2024, then skyrocketed by 80.62% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Long-Term Debt Repayments are $4.8 million (Q4 2025), $2.7 million (Q1 2025), and $2.7 million (Q3 2024).